Login to Your Account



Latest In A Series

Santaris and Pfizer Agree to $614M RNA Collaboration

By Tom Wall


Wednesday, January 5, 2011
Santaris Pharma A/S and Pfizer Inc. agreed to a deal potentially worth more than $614 million to extend their collaboration to develop and commercialize as many as 10 new RNA targets using Santaris' locked nucleic acid platform (LNA).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription